NDAORALCAPSULE
Approved
Oct 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TOLECTIN DS (tolmetin sodium) is a nonsteroidal anti-inflammatory drug (NSAID) approved in 1979 for the treatment of rheumatoid arthritis, osteoarthritis, and other inflammatory conditions. It functions as a cyclooxygenase inhibitor to reduce pain, inflammation, and fever in patients with chronic musculoskeletal disorders.
LOE Approaching
As an aging small-molecule NSAID approaching loss of exclusivity, the brand team is likely focused on cost containment and legacy market management with reduced commercial infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TOLECTIN DS offers minimal career advancement potential due to its LOE-approaching status, lack of linked job openings, and mature competitive position. Professionals assigned to this product should expect roles focused on legacy market management, generic pricing negotiation, and customer retention rather than growth or innovation.
Brand ManagerSales Representative
Worked on TOLECTIN DS at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.